Skip to main content
Premium Trial:

Request an Annual Quote

Roche Gets FDA Clearance for Strep A MDx Test

NEW YORK (GenomeWeb) – Roche announced today that it has received US Food and Drug Administration clearance for its cobas Strep A test for detecting group A streptococcus bacterial DNA in throat swab specimens.

The test runs on Roche's cobas Liat System, a molecular point-of-care diagnostic system scheduled for launch later this year. The PCR-based test can detect Strep A DNA in 15 minutes when run on the Liat system, Roche said.

Roland Diggelmann, COO of Roche Diagnostics, said in a statement that the test "provides a significant improvement over conventional methods such as culture testing, where patients can wait up to 2 days to receive their result, or rapid antigen testing where confirmation with culture is needed due to significantly lower sensitivity."

Roche gained the Liat (laboratory-in-a-tube) system through its acquisition earlier this year of IQuum. In addition to the system, IQuum had already gained FDA clearance for the Liat Influenza A/B assay, a rapid, near-patient test to detect and differentiate influenza A and B.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.